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Short Title: A tribute to Dr Robert Bittman 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract--With the passing of Dr. Robert Bittman on the 1st Oct 2014 from cancer, the lipid 
field lost its most distinguished lipid chemist researcher.  Herein, we provide a brief account 
of Dr. Robert Bittman’s research achievements over a 50 year career.  Dr. Robert Bittman’s 
lasting legacies to the fields of lipid membrane biophysics, cholesterol trafficking and cellular 
functions of phospholipids and sphingolipids are truly inestimable.   
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Dr Robert Bittman’s genius was in chemical design and eye to spot a complex biological 
problem that required solving.  Many scientists benefited enormously from Bob’s vocation.  
Some of the major breakthroughs in our current understanding of the role of lipids in 
constituting complex biophysical membranes, sterol transfer and participation in cellular 
communication networks were made achievable by unique chemical reagents devised by Bob.  
Bob published 322 peer-reviewed papers, contributed 64 book chapters and filed 19 US 
patents.  This prolific output reflects the energy and enthusiasm that Bob brought to 
integrating chemistry with topical biological research problems.  For this effort, Bob was 
funded continuously by the NIH grant mechanism from 1973 to the beginning of 2014, 
including a distinguished MERIT award from the National Heart Lung and Blood Institute 
from 1986. 
Bob enrolled at the City University of New York at the age of sixteen, where he majored in 
chemistry in 1962, and then completed a PhD in chemistry at University of California, 
Berkeley, under the mentorship of Andrew Streitwieser in 1965. For postdoctoral training, 
Bob joined the laboratory of Nobel Laureate Manfred Eigen at the Max Planck Institute for 
Physical Chemistry in Gottingen, Germany in 1965.  His first paper was published in ‘The 
Proceedings of the National Academy of Sciences’; a citation classic that Bob was immensely 
proud of.  This study involved deciphering the allosteric mechanism involved in binding of 
nicotinamide adenine dinucleotide to D-glyceraldehyde-3-phosphate dehydrogenase, 
employing analysis of temperature-jump relaxation kinetics (Kirschner et al. 1966).  In 1966, 
Bob joined the faculty of CUNY and became a Distinguished Professor of Chemistry and 
Biochemistry of Queens College and the Graduate Centre of CUNY in 1988.  Initially Bob 
focused on interaction of proteins, such as filipin with sterol-containing lipid vesicles and 
cellular membranes using spectral and electron microscopy and stop flow kinetic and 
equilibrium analysis (Bittman et al. 1974).  Bob published on the distribution of cholesterol 
between the outer and inner halves of the lipid bilayer of mycoplasma cell membranes 
(Bittman & Rottem, 1976) and the lack of effect of ester or ether linkages in 
phosphatidylcholine on the ability of cholesterol to reduce bilayer permeability (Bittman et al. 
1984).  There was also determination of the rates of rapidly exchanging cholesterol and 
phospholipid pools in sphingomyelin- and phosphatidylcholine-containing cells (Clejan et al. 
1984).   
From the mid-1990’s Bob’s interest in the role of lipids as mediators of cell function 
flourished.  He was instrumental in developing synthetic routes for platelet activating factor 
analogues and assessing their biological activity in cancer cells (Bittman et al. 1987; Salari et 
al. 1992).  Bob also developed a highly productive collaboration of Dr. Gilbert Arthur on the 
synthesis and biological assessment of ether lipids.  These ether lipids function as anti-tumour 
agents.  For instance, ET18-OCH3 induced inhibition of cell proliferation, Raf association 
with the membrane, and mitogen activated protein kinase activation (Zhou et al. 1996).  In the 
early 1990’s, Bob also collaborated with Dr. Richard Kolesnick in a foray into sphingolipid 
signalling.  This resulted in the demonstration that ceramide inhibits diacylglycerol kinase in 
cells (Younes et al. 1992), thereby establishing a reciprocal relationship between 
diacylglycerol and ceramide.  This was a very novel concept at that time, given its 
significance as a major factor in defining life or death of cells.  The collaboration also resulted 
in the synthesis of additional sphingolipids that enabled study of the structural/functional 
relationship of a newly-identified ceramide-activated protein kinase that was involved in 
mediating the effect of tumour necrosis factor alpha on differentiation of monocytic cancer 
cells (Joseph et al. 1993).   
Ceramide 1-phosphate had been characterised before, but Bob developed chemical synthetic 
routes from ceramide to produce this lipid (Byun et al. 1994).   With Drs. Antonio Gomez-
Muñoz and David Brindley there was further characterisation of the biological activity of 
ceramide 1-phosphate, specifically in fibroblasts where it stimulates proliferation (Gomez-
Muñoz et al. 1995).  This interest in ceramide biology grew exponentially over time, and Bob 
published many papers on novel synthetic routes for caged ceramide 1-phosphate 
(Lankalapall et al. 2009), phytoceramide and phytosphingosine (He et al. 2000), trans double 
bond sphingolipid analogues: '4 and '6 ceramides (Chun et al. 2001) and fluorescent 
lactosylceramide stereoisomers (Liu and Bittman, 2006).  There were also studies involving 
the use of D-C-galactosylceramide analogues to induce TH1-biased responses in human 
natural killer T-cells (Lu et al. 2006) and on characterisation of the recognition of CD1d-C-
galactosylceramide by natural killer T-cell receptor (Patel et al. 2011). 
Bob further demonstrated that sphingomyelin modulates transbilayer distribution of 
galactosylceramide in phospholipid membranes (Mattjus et al. 2002).  Using fluorescence 
quenching assays, there was also an assessment of the effect of ceramide on lipid raft 
organisation and sterol content (Megha et al. 2007).  At this time, Bob also synthesised 
BODIPY-cholesterol to visualise sterol trafficking in cells (Hölttä-Vuori et al. 2008). Indeed, 
BODIPY-cholesterol has recently been used to demonstrate that N-myc downstream-
regulated gene 1 (NDRG1) regulates low density lipoprotein (LDL) uptake by LDL receptor 
(Pietiäinen et al. 2013).   
Bob expansively turned his hand to synthesis of analogues of lysophosphatidic acid (LPA) 
and sphingosine 1-phosphate (S1P), bioactive lipids that bind to families of G-protein coupled 
receptors that function to programme cell responses, such as proliferation and migration.  In 
this regard, Bob established collaboration with Dr. Gabor Tigyi.  This resulted in synthesis of 
inhibitors of LPA receptors (Bittman et al. 1996), ligands (alkyl ether analogues or 
unsaturated acyl forms of LPA) of peroxisome proliferator-activated receptor J that promote 
neointimal formation (Zhang et al. 2004) and carba analogues of cyclic phosphatidic acid, 
which were used as selective inhibitors of autotaxin to block cancer cell invasion and 
metastasis (Baker et al. 2006).   
Bob’s interest in S1P expanded in 2003, to collaboration with many cutting edge research 
groups working in the area.  Seminal findings during this period included studies on the 
uptake and metabolism of S1P in lung endothelial cells (Zhao et al. 2007), inhibition of 
ceramide synthase by the sphingosine analogue FTY720 (Berdyshev et al. 2009), 
identification of erythrocytes as a major reservoir of S1P (Bode et al. 2010), and development 
of a novel assay for S1P lyase activity using labelled BODIPY-sphingosine 1-phosphate 
(Bandhuvula et al. 2009).  A highlight in this area was the synthesis of sphingadienes and 
characterisation of their biological activity in cancer. Collaboration with Dr. J. Saba revealed 
that sphingadienes induce colon cancer cell death by blocking AKT translocation to plasma 
membrane, promoting apoptosis and autophagy (Fyrst et al. 2009). Sphingadienes also down-
regulated the Wnt signalling program, which when dysregulated is a key driver of colon 
cancer tumourigenesis (Kumar et al. 2012).  Most recently, these workers found that up-
regulation of S1P lyase by dietary sphingadienes reduces colon carcinogenesis and is 
associated with down-regulation of S1P and Signal Transducer Activator of Transcription 3 
(STAT3), instigating relief from STAT3 activated miRNAs that suppress anti-oncogenes 
(Degagné et al. 2014).   
In the midst of all this activity, Bob developed a productive collaboration with Drs. Nigel and 
Susan Pyne, using the FTY720 scaffold (FTY720 is characterised as a functional antagonist 
of the S1P1 receptor marketed as the first oral treatment of relapsing multiple sclerosis under 
the trade name, GilenyaTM) to develop inhibitors of sphingosine kinase 1 and 2 (SK1 and 
SK2).  This included identification of (R)-FTY720 methyl ether, a selective SK2 inhibitor that 
prevents formation of actin-enriched lamellipodia typical of a migratory phenotype in breast 
cancer cells (Lim et al. 2011) and induces death of T cell acute lymphoblastic leukaemia cells 
(Evangelisti et al. 2014).  The collaboration also resulted in extensive analysis of structural 
activity relationships of SK1 selective inhibitors, including modelling into SK1 to establish 
optimal binding modalities (Baek et al. 2013). Such advances may significantly impact future 
development of SK inhibitors for therapeutic treatment of cancer. As Bob’s research 
accomplishments are many and his collaborations widespread, we apologise to those 
contributors who are not mentioned here. 
Bob’s research achievements were recognised by several plenary lectures (in Japan and 
Finland), and by awards including the Avanti Award of the American Society of 
Biochemistry and Molecular Biology in 2003 and a Fellowship from the AAAS in 2004.  He 
served on many Editorial Boards and NIH panels such as Organic Reactions (Secretary or Co-
Secretary, 1968-2014), Journal of Lipid Research (1985-2006), Biophysics Section of New 
York Academy of Sciences (Vice-Chairman, 1975-76; Chairman, 1977-78), N.I.H. 
Biophysical Chemistry Study Section, 1983, 1996, N.I.H. Panel on Minority Biomedical 
Research Support, 1991, N.I.H. Panel on the National Cooperative Drug Discovery Group, 
1991 and N.I.H. Panel - Program Project Reviews, 2000.  Bob was an excellent and patient 
teacher and mentor.  He trained over 20 post-doctoral and 23 graduate students.  Bob 
coordinated a Membrane Lipid Biochemistry course at the City University of New York that 
featured leading investigators in the lipid field. Both authors of this tribute had the pleasure to 
be involved in this teaching and one could recognise the high degree of respect he was 
regarded by his students.  Bob was a terrific tennis player and had an abiding interest in the 
performing arts.  He is survived by his wife, Marlene, and two children.  All of us will greatly 
miss Bob, who was, among other things, a distinguished scholar, an excellent teacher and 
mentor, and a very good friend and colleague. 
The City University of New York has established a memorial fund to honour Bob’s legacy to 
be used for the support and development of Chemistry and Biochemistry students at Queens 
College. Description of the Robert Bittman Memorial Fund can be found by visiting 
https://qccommunity.qc.cuny.edupages/funds/memory-of-dr-robert-bittman. 
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